On Jul. 16, 1952, the U.S. Food and Drug Administration (FDA) licensed a heat-phenol-inactivated whole-cell typhoid vaccine to Wyeth. The vaccine was associated with high rates of fever and systemic reactions was discontinued in 2000

Typhoid fever is uncommon in the United States, with an average of about 400 cases reported annually during 2007–2011. Approximately 90% of U.S. cases occur among persons returning from foreign travel, and >75% of travelers had been in India, Bangladesh, or Pakistan. Most travelers (≥55%) reported that their reason for travel was visiting friends or relatives. Even short-term travel to high-incidence areas is associated with risk for typhoid fever. CDC recommends typhoid vaccination for travelers to many Asian, African, and Latin American countries, but, as of 2010, no longer recommends typhoid vaccine for travelers to certain Eastern European and Asian countries

As of 2015, two typhoid vaccines were available for use in the United States: 1) a Vi capsular polysaccharide vaccine for parenteral use (Typhim Vi, manufactured by Sanofi Pasteur) and 2) an oral live-attenuated vaccine (Vivotif, manufactured from the Ty21a strain of Salmonella serotype Typhi by PaxVax).